

## 1 **Automated molecular testing of saliva for SARS-CoV-2 detection**

2 Nancy Matic<sup>1,2</sup>, Tanya Lawson<sup>1</sup>, Gordon Ritchie<sup>1,2</sup>, Aleksandra Stefanovic<sup>1,2</sup>, Victor Leung<sup>1,2</sup>,  
3 Sylvie Champagne<sup>1,2</sup>, Marc G. Romney<sup>1,2</sup>, Christopher F. Lowe<sup>1,2</sup>

4 <sup>1</sup> Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada

5 <sup>2</sup> Department of Pathology and Laboratory Medicine, University of British Columbia,  
6 Vancouver, Canada

### 7 8 **Abstract**

9 With surging global demand for increased SARS-CoV-2 testing capacity, clinical laboratories  
10 seek automated, high-throughput molecular solutions, particularly for specimen types which do  
11 not rely upon supply of specialized collection devices or viral transport media (VTM). Saliva  
12 was evaluated as a diagnostic specimen for SARS-CoV-2 using the cobas® SARS-CoV-2 Test  
13 on the cobas® 6800 instrument. Saliva specimens submitted from various patient populations  
14 under investigation for COVID-19 from March-July 2020 were processed in the laboratory with  
15 sterile phosphate-buffered saline in a 1:2 dilution and vortexed with glass beads. The processed  
16 saliva samples were tested using a commercial assay for detection of the SARS-CoV-2 E gene  
17 (LightMix®) in comparison to the cobas® SARS-CoV-2 Test. 22/64 (34.4%) of the saliva  
18 samples were positive for SARS-CoV-2. Positive and negative concordance between the  
19 LightMix® and cobas® assays were 100%. There was no cross-contamination of samples  
20 observed on the cobas® 6800. The overall invalid rate for saliva on the cobas® 6800 (1/128,  
21 0.78%) was similar to the baseline invalid rate observed for nasopharyngeal swabs/VTM and  
22 plasma samples. Saliva is a feasible specimen type for SARS-CoV-2 testing on the cobas®  
23 6800, with potential to improve turnaround time and enhance testing capacity.

## 24 **Introduction**

25 The global public health response to the COVID-19 pandemic highlighted the critical need for  
26 diagnostic testing which is sustainable, practical, rapid and scalable(1). With an increasing  
27 worldwide demand for SARS-CoV-2 molecular testing, supply-chain issues for high-quality,  
28 flocked nasopharyngeal (NP) swabs have created significant challenges for testing capacity in  
29 clinical and public health laboratories. Alternate specimen types, such as saliva, have been  
30 reported in some studies to have nearly comparable sensitivity to nasopharyngeal swabs for the  
31 detection of SARS-CoV-2, and may be an appropriate supplemental or alternate diagnostic  
32 specimen(2–4). Although a variety of methods for saliva collection have been described(2, 5, 6),  
33 we have previously shown the utility of testing saliva in the absence of transport media, which  
34 enables a simple collection technique that avoids the introduction of potential inhibitors(7, 8) and  
35 dependence on supply of specialized saliva collection devices.

36 In addition to potentially obviating supply shortages, saliva has been increasingly described as a  
37 useful sample for the diagnosis of COVID-19 to overcome certain pre-analytical collection  
38 challenges. Flocked NP swabs have been the preferred specimen type due to established  
39 sensitivity, but may occasionally result in false-negative test results due to poor specimen  
40 collection quality(9) or timing of testing relative to symptom onset(10–12). Lower respiratory  
41 tract specimens such as a bronchoalveolar lavage are often obtained from severely ill patients,  
42 but require aerosol-generating medical procedures and thus have the potential for aerosolization  
43 and transmission of SARS-CoV-2. Furthermore, only a minority of patients with COVID-19 are  
44 able to produce expectorated sputum(13). Saliva is a convenient alternate sample to collect for  
45 SARS-CoV-2 detection, particularly for patients with high clinical suspicion for COVID-19 but

46 repeatedly negative test results by NP swabs(14, 15) or for individuals unwilling or unable to  
47 tolerate NP swab collection.

48 Within our clinical laboratory, processing and testing of saliva is currently a manual process  
49 requiring extraction (MagNA Pure Compact or MagNA Pure 96, Roche Molecular Diagnostics,  
50 Pleasanton, CA) followed by amplification (LightCycler 480, Roche). Post-analytical reporting  
51 into the electronic medical records system is also a manual process. As a result, capacity for  
52 saliva testing in our laboratory is limited, with delays in turnaround time compared to  
53 nasopharyngeal swabs which are processed entirely on the automated cobas® 6800 (Roche). We  
54 sought to evaluate the potential utilization of the cobas® 6800 for SARS-CoV-2 detection from  
55 saliva.

56

## 57 **Materials and Methods**

58 From March-July 2020, saliva was ordered by clinicians from both hospitalized and ambulatory  
59 patients for the diagnosis of COVID-19. Briefly,  $\geq 1$ mL of saliva was collected in a sterile  
60 screw-top container (Starplex Scientific Inc., Etobicoke, Canada) without the addition of  
61 transport media, and then processed in the virology laboratory with phosphate-buffered saline  
62 (PBS) in a 1:2 dilution and glass beads. Samples were tested using the LightMix® ModularDx  
63 SARS-CoV (COVID19) E-gene assay (TIB Molbiol, Berlin, Germany), with use of the MagNA  
64 Pure Compact or MagNA Pure 96 and LightCycler 480. The remaining volume of processed  
65 saliva samples was stored at  $-70^{\circ}\text{C}$ . Processed saliva samples were then tested with the cobas®  
66 SARS-CoV-2 Test (Roche Molecular Diagnostics, Laval, QC) on the cobas® 6800. Prior to  
67 cobas® SARS-CoV-2 testing, a software upgrade (Assay Specific Analysis Package [ASAP])  
68 was required on the cobas® 6800 to prevent viscous specimens from mistakenly being

69 interpreted as clotted/invalid by the instrument. Samples known to be positive for SARS-CoV-2  
70 based on results from the LightMix® assay were alternated with negative samples in a  
71 checkerboard pattern on the 96-well processing plate, and tested in duplicate.

72

## 73 **Results**

74 A total of 64 clinical saliva samples were included and tested in duplicate for SARS-CoV-2 on  
75 the cobas® 6800. Twenty-two (34.4%) of the samples were known to be positive for SARS-  
76 CoV-2 based on prior results from the LightMix® assay, and 42 (65.6%) had no detectable  
77 SARS-CoV-2. Compared to the LightMix® assay, positive percent agreement and negative  
78 percent agreement on the cobas® 6800 were 100%. The median cycle threshold (Ct) values for  
79 detection of the Envelope (E) gene were comparable between the cobas® 6800 (28.82,  
80 interquartile range [IQR] 7.29) and the LightMix® assay (26.63, IQR 7.61) (**Figure 1**). No  
81 carryover or cross-contamination of samples was observed, even with strongly positive samples  
82 (Ct values 13 to 24) directly adjacent to negative samples. One saliva sample produced an error  
83 which was reported by the cobas 6800® instrument as ‘Invalid’; this sample was successfully  
84 tested on the duplicate run. In total, the observed error rate for saliva samples tested on the  
85 cobas® 6800 was 0.78% (1/128).

86

## 87 **Discussion**

88 In our evaluation of the cobas® 6800 for saliva testing, we demonstrated complete concordance  
89 in comparison to the LightMix® assay, which is the current assay utilized in our laboratory for  
90 clinical testing of specimens other than NP swabs such as saliva.

91 Previous studies have evaluated the feasibility of saliva for SARS-CoV-2 detection on  
92 commercial instruments such as the Cepheid GeneXpert® System(16) and cobas® 8800(12).  
93 However, there are technical challenges associated with processing saliva for automated, high-  
94 throughput testing. As a highly viscous sample compared to viral transport media, there is  
95 potential for pipetting errors or instrument contamination. In our laboratory, saliva is pre-  
96 processed with sterile PBS and glass beads in order to decrease the viscosity of the sample. The  
97 samples utilized in the study were from a variety of clinical situations, including long-term care  
98 residents, inpatients at a tertiary care hospital, and outpatient contacts of known COVID-19  
99 patients; these samples would be broadly representative of saliva ordered and collected for  
100 clinical testing in the future. Reassuringly, testing with this specimen type did not result in a  
101 significant number of invalid results (1/128, 0.78%), and was comparable to the rate of invalid  
102 results observed in our laboratory from nasopharyngeal swabs with the SARS-CoV-2 Test  
103 (0.20%) and plasma used with other cobas® 6800 assays (0.30%) (unpublished data). We also  
104 assessed the potential for carryover during pipetting on the cobas® by testing positive samples  
105 alternated with negative samples in a checkerboard pattern, and did not identify any cross-  
106 contamination of samples.

107 This study is limited by the retrospective testing of stored saliva samples. Clinical testing was  
108 performed in real time on the LightMix® assay, and samples were stored for subsequent testing  
109 on the cobas® after the software had been upgraded. Although testing was not performed in  
110 parallel, there was high concordance of testing despite sample storage. Furthermore, testing of  
111 retrospective samples was necessary to ensure a sufficient number of saliva samples with  
112 detectable SARS-CoV-2 RNA were included.

113 Due to limited remnant sample volume in some cases, five of the twenty-two saliva samples  
114 positive for SARS-CoV-2 (22.7%) underwent additional dilution with sterile PBS in order to test  
115 on the cobas® 6800. The Ct values in these cases cannot be directly compared to those from the  
116 LightMix® assay as a measure of assay performance; however, the dilution factor in these cases  
117 (1:3 to 1:5) would have had a negligible effect on the Ct values, and the aim of this study was to  
118 assess the technical feasibility of saliva samples for automated, high-throughput SARS-CoV-2  
119 testing on the cobas® 6800.

120 Transitioning to an automated platform for saliva testing is critical for enhancing SARS-CoV-2  
121 testing capacity, particularly in preparation for a potential resurgence of COVID-19 cases or  
122 mass testing of defined populations. Automated testing reduces errors in the pre-analytical and  
123 post-analytical phases, and improves turnaround time by enabling saliva to be processed on  
124 multiple runs per day (including overnight testing). Our evaluation confirmed the feasibility of  
125 saliva as a suitable specimen type for SARS-CoV-2 testing on the cobas® 6800 platform.

126

## 127 **Acknowledgements**

128 We are grateful to our medical laboratory technologists who are highly committed to patient care  
129 and laboratory quality improvement.

130 This study was supported by Roche Diagnostics for a software upgrade of the cobas® 6800, but  
131 no financial compensation was provided. Roche Diagnostics was not involved in the study  
132 design, implementation nor analysis of the data.

133 This study received approval from the Providence Health Care Research Ethics Board.

134

## 135 **Potential Conflicts of Interest**

136 N.M. reports honoraria related to speaker engagement outside the submitted work for Roche  
137 Molecular Systems, Inc. All other authors report no relevant conflicts of interest.

138

## 139 **References**

- 140 1. (WHO) WHO. 2020. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in  
141 suspected human cases.
- 142 2. To KKW, Tsang OTY, Leung WS, Tam AR, Wu TC, Lung DC, Yip CCY, Cai JP, Chan  
143 JMC, Chik TSH, Lau DPL, Choi CYC, Chen LL, Chan WM, Chan KH, Ip JD, Ng ACK,  
144 Poon RWS, Luo CT, Cheng VCC, Chan JFW, Hung IFN, Chen Z, Chen H, Yuen KY.  
145 2020. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum  
146 antibody responses during infection by SARS-CoV-2: an observational cohort study.  
147 *Lancet Infect Dis* 3099:1–10.
- 148 3. Jamal AJ, Mozafarihashjin M, Coomes E, Powis J, Li AX, Paterson A, Anceva-Sami S,  
149 Barati S, Crowl G, Faheem A, Farooqi L, Khan S, Prost K, Poutanen S, Taylor M, Yip L,  
150 Zhong XZ, McGeer AJ, Mubareka S. 2020. Sensitivity of nasopharyngeal swabs and  
151 saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-  
152 2). *Clin Infect Dis* 27:9–11.
- 153 4. Williams E, Bond K, Zhang B, Putland M, Williamson DA. 2020. Saliva as a non-  
154 invasive specimen for detection of SARS-CoV-2. *J Clin Microbiol* 50.
- 155 5. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar  
156 P, Geng B, Muenker MC, Moore AJ, Vogels CBF, Petrone ME, Ott IM, Lu P, Lu-  
157 Culligan A, Klein J, Venkataraman A, Earnest R, Simonov M, Datta R, Handoko R,  
158 Naushad N, Sewanan LR, Valdez J, White EB, Lapidus S, Kalinich CC, Jiang X, Kim DJ,

- 159 Kudo E, Linehan M, Mao T, Moriyama M, Oh JE, Park A, Silva J, Song E, Takahashi T,  
160 Taura M, Weizman O-E, Wong P, Yang Y, Bermejo S, Odio C, Omer SB, Cruz CS Dela,  
161 Farhadian S, Martinello RA, Iwasaki A, Grubaugh ND, Ko AI. 2020. Saliva is more  
162 sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs.  
163 medRxiv 2020.04.16.20067835.
- 164 6. Azzi L, Carcano G, Gianfagna F, Grossi P, Gasperina DD, Genoni A, Fasano M, Sessa F,  
165 Tettamanti L, Carinci F, Maurino V, Agostino R, Tagliabue A, Baj A. 2020. SALIVA IS  
166 A RELIABLE TOOL TO DETECT SARS-CoV-2. *J Infect* 1–6.
- 167 7. Rodríguez A, Vaneechoutte M. 2019. Comparison of the efficiency of different cell lysis  
168 methods and different commercial methods for RNA extraction from *Candida albicans*  
169 stored in RNAlater. *BMC Microbiol* 19:1–10.
- 170 8. Jiang L, Li L, Kang P, Yu H, Nie SP, Xie MY, Gong J. 2019. Inappropriateness of  
171 RNAlater to preserve *Caenorhabditis elegans* for RNA extraction. *MethodsX* 6:2460–  
172 2467.
- 173 9. Kinloch N, Ritchie G, Brumme CJ, Dong W, Dong W, Lawson T, Jones RB, Montaner  
174 JSG, Leung V, Romney MG, Stefanovic A, Matic N, Lowe CF BZ. 2020. Suboptimal  
175 biological sampling as a probable cause of false-negative COVID-19 diagnostic test  
176 results. *J Infect Dis* 1–4.
- 177 10. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D,  
178 Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmman  
179 R, Zwirgmaier K, Drosten C, Wendtner C. 2020. Virological assessment of hospitalized  
180 patients with COVID-2019. *Nature* 1–14.
- 181 11. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, Lau YC, Wong JY, Guan Y, Tan X, Mo




- 182 X, Chen Y, Liao B, Chen W, Hu F, Zhang Q, Zhong M, Wu Y, Zhao L, Zhang F, Cowling  
183 BJ, Li F, Leung GM. 2020. Temporal dynamics in viral shedding and transmissibility of  
184 COVID-19. *Nat Med* 26:672–675.
- 185 12. Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, Horiuchi M, Kato  
186 K, Imoto Y, Iwata M, Mimura S, Ito T, Tamura K, Kato Y. 2020. Clinical evaluation of  
187 self-collected saliva by RT-qPCR, direct RT-qPCR, RT-LAMP, and a rapid antigen test to  
188 diagnose COVID-19. *J Clin Microbiol*.
- 189 13. Huang C, Wang Y, Li Z, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu  
190 T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Hao H, Guo L, Xie J, Wang  
191 G, Jiang R, Gao Z, Hin Q, Wang J CB. 2020. Since January 2020 Elsevier has created a  
192 COVID-19 resource centre with free information in English and Mandarin on the novel  
193 coronavirus COVID- research that is available on the COVID-19 resource centre -  
194 including this ScienceDirect Clinical characteris. *Lancet* 395:497–506.
- 195 14. Koven S. 2020. Engla, Journal - 2010 - New engla nd journal. *N Engl J Med* 38:1–2.
- 196 15. Watson J, Whiting PF, Brush JE. 2020. Interpreting a covid-19 test result. *BMJ* 369:1–7.
- 197 16. McCormick-Baw C, Morgan K, Gaffney D, Cazares Y, Jaworski K, Byrd A, Molberg K,  
198 Cavuoti D. 2020. Saliva as an Alternate Specimen Source for Detection of SARS-CoV-2  
199 in Symptomatic Patients Using Cepheid Xpert Xpress SARS-CoV-2. *J Clin Microbiol*  
200 58:2–3.

201

202

203

204



205

206 **Figure 1:** No significant difference in median cycle threshold (Ct) values for the Envelope (E)  
207 gene was observed in saliva samples positive for SARS-CoV-2, using the LightMix®  
208 ModularDx SARS-CoV (COVID19) E-gene assay (TIB Molbiol, Berlin, Germany) and the  
209 cobas® SARS-CoV-2 Test (Roche Molecular Diagnostics, Laval, QC) on the cobas® 6800  
210 platform.